Parul Sharma Joins ScreenPoint Medical as New Chief Commercial Officer to Drive Growth
Parul Sharma Joins ScreenPoint Medical as Chief Commercial Officer
ScreenPoint Medical has made an important addition to its management team by welcoming Parul Sharma as the new Chief Commercial Officer (CCO). This strategic appointment comes at a time when the company seeks to accelerate its commercial momentum and leadership in AI-driven breast cancer solutions globally.
Since her ascent in 2016 to various C-level commercial roles in different software sectors, Parul has built a robust career heading commercial strategies for companies including Hansoft, Besedo, and Bannerflow. Her most recent position before joining ScreenPoint was as CCO at Viedoc, an Electronic Data Capture platform that provides crucial support for clinical trials.
With a strong emphasis on blending innovative technology with clinical insights, Parul shared her enthusiasm for ScreenPoint Medical. She expressed, "What attracted me to ScreenPoint Medical is the opportunity to bring together innovative technology and strong clinical evidence that translates into meaningful impact for women." Her passion for this cause is coupled with a commitment to advance the company's global presence and increase the adoption of its Breast AI technology, known as Transpara.
ScreenPoint Medical has achieved notable progress in the AI breast cancer detection space, having processed over 15 million mammograms globally. The company aims to expand its footprint across the U.S., Europe, and beyond, amidst rising demand for AI-driven solutions in healthcare settings. In the last year, it has bolstered its involvement in important clinical research and randomized controlled trials such as MASAI, PRISM, and AIMS.
Pieter Kroese, CEO of ScreenPoint Medical, remarked on the significance of Parul's appointment, stating, "Parul has a proven track record of working alongside teams and organisations as they translate new technologies into tangible outcomes." His optimism about the future of ScreenPoint Medical under her leadership echoes the confidence the company has in scaling its operations.
Parul's educational background includes an undergraduate degree in Biochemistry from Delhi University, followed by a postgraduate degree in Brand Management from the Mudra Institute of Communications. Currently residing in Stockholm, her extensive experience promises to drive significant results for ScreenPoint Medical.
In the ongoing battle against breast cancer, every mammogram represents an opportunity for advancement in detection and insights. ScreenPoint Medical's commitment to research and innovation, encapsulated in Transpara Breast AI, is recognized by radiologists and patients alike.
With this latest leadership change, ScreenPoint Medical is positioning itself to transform the field of breast health and amplify its impact on patient care across the globe.